Journal of Applied Physiology Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Appl Physiol 103: 1441-1448, 2007. First published July 5, 2007; doi:10.1152/japplphysiol.00642.2007
8750-7587/07 $8.00
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
103/4/1441    most recent
00642.2007v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (16)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vinten-Johansen, J.
Right arrow Articles by Dobson, G. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vinten-Johansen, J.
Right arrow Articles by Dobson, G. P.

INVITED REVIEW

HIGHLIGHTED TOPIC
Perspectives in Innate and Acquired Cardioprotection

Preconditioning and postconditioning: innate cardioprotection from ischemia-reperfusion injury

Jakob Vinten-Johansen,1 Zhi-Qing Zhao,1 Rong Jiang,1 Amanda J. Zatta,2 and Geoffrey P. Dobson3

1Cardiothoracic Research Laboratory, Carlyle Fraser Heart Center of Emory University and Emory Crawford Long Hospital, Atlanta, Georgia; 2Baker Heart Research Institute, Melbourne, Victoria; and 3Department Physiology and Pharmacology, James Cook University, Townsville, Queensland, Australia

Reperfusion is the definitive treatment to salvage ischemic myocardium from infarction. A primary determinant of infarct size is the duration of ischemia. In myocardium that has not been irreversibly injured by ischemia, reperfusion induces additional injury in the area at risk. The heart has potent innate cardioprotective mechanisms against ischemia-reperfusion that reduce infarct size and other presentations of postischemic injury. Ischemic preconditioning (IPC) applied before the prolonged ischemia exerts the most potent protection observed among known strategies. It has been assumed that IPC exerts protection during ischemia. However, recent data suggest that cardioprotection is also exerted during reperfusion. Postconditioning (PoC), defined as brief intermittent cycles of ischemia alternating with reperfusion applied after the ischemic event, has been shown to reduce infarct size, in some cases equivalent to that observed with IPC. Although there are similarities in mechanisms of cardioprotection by these two interventions, there are key differences that go beyond simply exerting these mechanisms before or after ischemia. A significant limitation of IPC has been the inability to apply this maneuver clinically except in situations where the ischemic event can be predicted. On the other hand, PoC is applied at the point of service in the hospital (cath-lab for percutaneous coronary intervention, coronary artery bypass grafting, and other cardiac surgery) where and when reperfusion is initiated. Initial clinical studies are in agreement with the success and extent to which PoC reduces infarct size and myocardial injury, even in the presence of multiple comorbidities.

ischemia; infarction; infarct size; reperfusion injury; myocardium; inflammation



Address for reprint requests and other correspondence: J. Vinten-Johansen, Cardiothoracic Research Laboratory of Emory Crawford Long Hospital and Emory Univ., 550 Peachtree St NE, Atlanta, GA 30308-2225 (e-mail: jvinten{at}emory.edu)




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
L. Gomez, B. Li, N. Mewton, I. Sanchez, C. Piot, M. Elbaz, and M. Ovize
Inhibition of mitochondrial permeability transition pore opening: translation to patients
Cardiovasc Res, July 15, 2009; 83(2): 226 - 233.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Granfeldt, D. J. Lefer, and J. Vinten-Johansen
Protective ischaemia in patients: preconditioning and postconditioning
Cardiovasc Res, July 15, 2009; 83(2): 234 - 246.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
I. Hecht, J. Rong, A. L. F. Sampaio, C. Hermesh, C. Rutledge, R. Shemesh, A. Toporik, M. Beiman, L. Dassa, H. Niv, et al.
A Novel Peptide Agonist of Formyl-Peptide Receptor-Like 1 (ALX) Displays Anti-Inflammatory and Cardioprotective Effects
J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 426 - 434.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Z. Yang, J. Linden, S. S. Berr, I. L. Kron, G. A. Beller, and B. A. French
Timing of adenosine 2A receptor stimulation relative to reperfusion has differential effects on infarct size and cardiac function as assessed in mice by MRI
Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2328 - H2335.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Thibault, C. Piot, P. Staat, L. Bontemps, C. Sportouch, G. Rioufol, T. T. Cung, E. Bonnefoy, D. Angoulvant, J.-F. Aupetit, et al.
Long-Term Benefit of Postconditioning
Circulation, February 26, 2008; 117(8): 1037 - 1044.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.